UK MHRA investigates peptide clinics, GoodRx matches oral semaglutide pricing, FDA approves Eli Lilly oral GLP-1, and India tightens GLP-1 oversight.
10 stories · Covering regulatory, industry, research, clinical-trials
The UK dominates today's peptide headlines as the MHRA launches an investigation into clinics making medicinal claims for unregulated peptides like BPC-157 and Thymosin Alpha, alongside two major explainer pieces from The Guardian and The Spectator examining the safety gap in the booming $50B peptide market. Stateside, the GLP-1 price war heats up with GoodRx announcing it will match Novo Nordisk's pricing for oral semaglutide, while the FDA and Novo Nordisk signal an aggressive crackdown on compounded GLP-1 telehealth operations. India is also tightening its regulatory grip on GLP-1 drugs ahead of semaglutide's patent expiry.
The MHRA is investigating whether UK peptide clinics are breaking the law by making medicinal claims for unregulated peptides like BPC-157 and Thymosin Alpha. Clinics were found charging £350–£450/month per peptide despite labeling them "research only."
GoodRx announced oral semaglutide availability via its telemedicine platform at $149 for lower doses, matching Novo Nordisk pricing and intensifying the GLP-1 price war.
The FDA announced steps to restrict compounded GLP-1 products, specifically naming Hims & Hers. Novo Nordisk has also sued Hims & Hers over compounded semaglutide.
India's drug regulators are intensifying GLP-1 oversight ahead of semaglutide's patent expiry. The Drug Controller General audited 49 entities and issued notices to violators.
The regulated peptide market is worth $50 billion and projected to double by the early 2030s. Unregulated peptides like BPC-157 and TB-500 lack rigorous human safety data and are increasingly sourced from gray-market Chinese distributors.
Eli Lilly's Foundayo (orforglipron) won FDA approval with aggressive pricing as low as $25/month with savings card. Medicare Part D coverage could bring costs to $50/month starting July 2026.
Comprehensive look at peptide therapies from approved GLP-1s to unregulated substances like BPC-157 and TB-500. Most evidence comes from animal studies, with benefits "largely unvalidated in human trials."
The FLOW trial showed semaglutide reduced major kidney disease events by ~24%, while the SELECT trial found a 20% reduction in major adverse cardiovascular events among 17,600+ adults.
The 25-mg oral semaglutide formulation broadens GLP-1 access for chronic weight management, with pharmacists playing a key role in patient counseling and adherence support.
Orforglipron (Foundayo) is the first GLP-1 pill that can be taken at any time without food or water restrictions, a major differentiator from oral semaglutide which requires morning dosing on an empty stomach.